EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

Shorena Janelidze iD, Divya Bali, Nicholas J Ashton, Nicolas R Barthélemy, Jeroen Vanbrabant, Erik Stoops, Eugeen Vanmechelen, Yingxin He iD, Anna Orduña Dolado, Gallen Triana-Baltzer, Michael J Pontecorvo, Henrik Zetterberg iD und 5 weitere

Brain · 19.04.2023 · 146 (4) · 1592-1601

DOI: 10.1093/brain/awac333 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 10.09.2022. Verfasst von Shorena Janelidze und 16 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Memory Research Unit, Lund University, Lund, Sweden. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 537-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS, NIA NIH HHS, Swedish Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p-tau181, p-tau217 and p-tau231 measured using 10 assays to detect abnormal brain amyloid-β (Aβ) status and predict future progression to Alzheimer's dementia. The study included 135 patients with baseline diagnosis of mild cognitive impairment (mean age 72.4 years; 60.7% women) who were followed for an average of 4.9 years. Seventy-one participants had abnormal Aβ-status (i.e. abnormal CSF Aβ42/40) at baseline; and 45 of these Aβ-positive participants progressed to Alzheimer's dementia during follow-up. P-tau concentrations were determined in baseline plasma and CSF. P-tau217 and p-tau181 were both measured using immunoassays developed by Lilly Research Laboratories (Lilly) and mass spectrometry assays developed at Washington University (WashU). P-tau217 was also analysed using Simoa immunoassay developed by Janssen Research and Development (Janss). P-tau181 was measured using Simoa immunoassay from ADxNeurosciences (ADx), Lumipulse immunoassay from Fujirebio (Fuji) and Splex immunoassay from Mesoscale Discovery (Splex). Both p-tau181 and p-tau231 were quantified using Simoa immunoassay developed at the University of Gothenburg (UGOT). We found that the mass spectrometry-based p-tau217 (p-tau217WashU) exhibited significantly better performance than all other plasma p-tau biomarkers when detecting abnormal Aβ status [area under curve (AUC) = 0.947; Pdiff < 0.015] or progression to Alzheimer's dementia (AUC = 0.932; Pdiff < 0.027). Among immunoassays, p-tau217Lilly had the highest AUCs (0.886–0.889), which was not significantly different from the AUCs of p-tau217Janss, p-tau181ADx and p-tau181WashU (AUCrange 0.835–0.872; Pdiff > 0.09), but higher compared with AUC of p-tau231UGOT, p-tau181Lilly, p-tau181UGOT, p-tau181Fuji and p-tau181Splex (AUCrange 0.642–0.813; Pdiff ≤ 0.029). Correlations between plasma and CSF values were strongest for p-tau217WashU (R = 0.891) followed by p-tau217Lilly (R = 0.755; Pdiff = 0.003 versus p-tau217WashU) and weak to moderate for the rest of the p-tau biomarkers (Rrange 0.320–0.669). In conclusion, our findings suggest that among all tested plasma p-tau assays, mass spectrometry-based measures of p-tau217 perform best when identifying mild cognitive impairment patients with abnormal brain Aβ or those who will subsequently progress to Alzheimer's dementia. Several other assays (p-tau217Lilly, p-tau217Janss, p-tau181ADx and p-tau181WashU) showed relatively high and consistent accuracy across both outcomes. The results further indicate that the highest performing assays have performance metrics that rival the gold standards of Aβ-PET and CSF. If further validated, our findings will have significant impacts in diagnosis, screening and treatment for Alzheimer's dementia in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionHumansFemaleAgedMaletau ProteinsAmyloid beta-PeptidesBrainBiomarkers

Stichwörter der Autor:innen

Alzheimer’s diseaseamyloid-βblood p-taudementia

Substanzen

tau ProteinsAmyloid beta-PeptidesBiomarkers

Autor:innen und Institutionen

  • Clinical Memory Research Unit, Lund University, Lund, Sweden.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
  • Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.
  • NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK.
  • Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.
  • Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.

ORCID-Profile: Shorena Janelidze, Yingxin He, Henrik Zetterberg, Oskar Hansson

Förderung

  • NINDS NIH HHS
  • NIA NIH HHS
  • Swedish Research Council
  • Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
  • Skåne University Hospital
  • Alzheimer Drug Discovery Foundation
  • Joint Programme – Neurodegenerative Disease Research

Zitieren

APA

Janelidze, S., Bali, D., Ashton, N. J., Barthélemy, N. R., Vanbrabant, J., Stoops, E., Vanmechelen, E., He, Y., Dolado, A. O., Triana-Baltzer, G., Pontecorvo, M. J., Zetterberg, H., Kolb, H., Vandijck, M., Blennow, K., Bateman, R. J., & Hansson, O. (2023). Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. Brain, 146(4), 1592-1601. https://doi.org/10.1093/brain/awac333

Vancouver

Janelidze S, Bali D, Ashton NJ, Barthélemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. Brain. 2023;146(4):1592-1601. doi:10.1093/brain/awac333

BibTeX
@article{Janelidze2023,
  author = {Janelidze, Shorena and Bali, Divya and Ashton, Nicholas J and Barthélemy, Nicolas R and Vanbrabant, Jeroen and Stoops, Erik and Vanmechelen, Eugeen and He, Yingxin and Dolado, Anna Orduña and Triana-Baltzer, Gallen and Pontecorvo, Michael J and Zetterberg, Henrik and Kolb, Hartmuth and Vandijck, Manu and Blennow, Kaj and Bateman, Randall J and Hansson, Oskar},
  title = {Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease},
  journal = {Brain},
  year = {2023},
  volume = {146},
  number = {4},
  pages = {1592--1601},
  doi = {10.1093/brain/awac333}
}
Kostenlos starten →